Safety of early antiplatelet therapy in non-cardioembolic mild stroke patients with thrombocytopenia

To investigate the safety of early antiplatelet therapy in non-cardioembolic mild stroke patients with thrombocytopenia. Data of acute ischemic stroke patients with baseline National Institutes of Health Stroke scale (NIHSS) score ≤3 and a platelet count 0.05), but increased the risk of gastrointestinal bleeding ( =2.837, 95% : 1.311-6.136, 90×10 /L, antiplatelet therapy significantly improved neurological functional outcomes ( 75-90)×10 /L, antiplatelet therapy resulted in a significant improvement of 1-year survival ( 0.05) and improved neurological functional outcomes (all 0.05). For non-cardioembolic mild stroke patients with thrombocytopenia, antiplatelet therapy is still reasonable. Mono-antiplatelet therapy has the same efficiency as dual-antiplatelet therapy in neurological outcome improvement with lower risk of gastrointestinal bleeding.